SCHEMBL6350943

SCHEMBL6350943

Cc1ccc(Nc2cc(N(C)C)nc(N3CCN(c4ccccn4)CC3)n2)cc1NC(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR2 O43603 6/20 0.42
MAPT P10636 4/20 0.40
TSHR P16473 3/20 0.40
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LCK P06239 1/20 0.40
GALR1 P47211 6/20 0.39
ALDH1A1 P00352 5/20 0.37
POLB P06746 3/20 0.37
PHGDH O43175 1/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PANK3 Q9H999 1/20 0.36
GAA P10253 1/20 0.36
BRAF P15056 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240352 0.89 GALR2 (0.46) GALR2MAPTTSHRKDM4ELMNA
SCHEMBL3247614 0.88 MAPT (0.45) GALR2MAPTTSHRKDM4ELMNA
SCHEMBL8092857 0.86 MAPT (0.51) GALR2MAPTTSHRKDM4ELMNA
SCHEMBL3240471 0.85 MAPT (0.43) GALR2MAPTTSHRKDM4ELMNA
SCHEMBL6353567 0.85 GALR2 (0.43) GALR2MAPTTSHRKDM4ELMNA
SCHEMBL8254119 0.84 KDM4E (0.48) GALR2MAPTTSHRKDM4ELMNA
SCHEMBL3246542 0.83 L3MBTL1 (0.47) GALR2MAPTTSHRKDM4ELMNA
SCHEMBL3242654 0.83 GALR2 (0.53) GALR2MAPTTSHRKDM4ELMNA
SCHEMBL3244443 0.82 PHGDH (0.47) GALR2MAPTTSHRKDM4ELMNA
SCHEMBL3236306 0.81 HTR1A (0.41) GALR2MAPTTSHRKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936607-B2 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNOBECK A/S (DK) 2005-08-30 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety GALR3, GALR2, GALR1 GALR2 2/4885MAPT 2638/4885TSHR 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.